Company Filing History:
Years Active: 2019
Title: R Max Wynn: Innovator in Mitochondrial Research
Introduction
R Max Wynn is a notable inventor based in Hurst, TX (US). He has made significant contributions to the field of mitochondrial research, particularly in the development of inhibitors for mitochondrial pyruvate dehydrogenase kinase (PDK) isoforms. His work aims to address critical health issues such as diabetes, cardiovascular disease, and cancer.
Latest Patents
Wynn holds a patent titled "Inhibitors of mitochondrial pyruvate dehydrogenase kinase isoforms 1-4 and uses thereof." This patent focuses on the identification of PDK inhibitors and their therapeutic applications. The invention emphasizes the development of robust PDK inhibitors that enhance glucose metabolism and rectify metabolic dysfunction in vivo. By modifying a known Hsp90 inhibitor, Wynn's approach has led to the creation of a highly specific inhibitor for all PDK isoforms. These inhibitors effectively augment PDC activity while minimizing phosphorylation in tissues.
Career Highlights
Wynn is affiliated with the University of Texas System, where he continues to advance his research in mitochondrial function and metabolic diseases. His innovative work has positioned him as a key figure in the scientific community, particularly in the realm of metabolic health.
Collaborations
Wynn has collaborated with esteemed colleagues such as David T Chuang and Shih-Chia Tso. These partnerships have further enriched his research endeavors and contributed to the advancement of knowledge in the field.
Conclusion
R Max Wynn's contributions to mitochondrial research and his innovative patent for PDK inhibitors highlight his commitment to improving health outcomes. His work continues to pave the way for new therapeutic strategies in the treatment of metabolic diseases.